FDA Approves Auvelity for Alzheimer's Agitation, Expanding Treatment Options
In April 2026, the FDA approved Auvelity, marking it as the first non-antipsychotic treatment for agitation in Alzheimer's patients. This approval is significant as agitation affects up to 76% of Alzheimer's patients and poses a major challenge for caregivers. The approval is currently limited to the U.S., highlighting the need for real-world evidence to evaluate the effectiveness of such treatments. The therapeutic landscape for Alzheimer's is evolving, with a focus on symptomatic treatments and novel mechanisms of action, beyond traditional amyloid-targeting therapies. 
